Sequana Medical NV, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, has confirmed the appointments of Pierre Chauvineau as Chairman and Wim Ottevaere as non-executive director of the Company effective as of the closing of the intended Initial Public Offering. Pierre will succeed Rudy Dekeyser as Chairman, who will remain a non-executive director.
Pierre has over 27 years of international business leadership experience within the MedTech industry. He currently serves as an executive advisor for Boston Scientific EMEA, and previously served as Vice President and General Manager of Boston Scientific’s European Rhythm Management Business Unit. Pierre’s earlier roles include Vice President and General Manager International at Cameron Health, a VC-funded medical device company based in California, where he led the commercialisation of the world’s first commercially available subcutaneous implantable cardioverter defibrillator (S-ICD®). The company was acquired by Boston Scientific in 2012 in a deal valued at approximately $1.35 billion. Prior to joining Cameron Health, Pierre served in various business and regional leadership roles at Medtronic in Europe, where he contributed to the growth of the European business.
Wim brings 40 years of experience in finance, of which 26 years have been within the BioTech industry, and successfully completed numerous public and private capital increases. He was the Chief Financial Officer of Ablynx until September 2018, a Belgian biopharmaceutical company listed on Euronext Brussels and Nasdaq until its acquisition by Sanofi for €3.9 billion in June 2018. Before joining Ablynx in 2006, Wim was Chief Financial Officer of Euronext Brussels-listed biotech company Innogenetics (now Fujirebio Europe NV). Prior to that, he held numerous senior management positions in finance and administration.
